



Anais Brasileiros de Dermatologia

www.anaisdedermatologia.org.br



CONTINUING MEDICAL EDUCATION

Primary cutaneous cryptococcosis – History, concepts, clinical and therapeutic update[☆]



Sílvio Alencar Marques *, Rosângela Maria Pires de Camargo

Department of Infectology, Dermatology, Diagnostic Imaging and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil

Received 18 April 2024; accepted 15 July 2024
Available online 15 November 2024

KEYWORDS

Clinical medicine;
Cryptococcosis;
Cryptococcosis/diagnosis;
Cryptococcosis/therapy;
Mycology

Abstract Cryptococcosis is a disease caused by fungi of the genus *Cryptococcus*, with the species *Cryptococcus neoformans* and *Cryptococcus gattii* being recognized as pathogenic. Cutaneous cryptococcosis can be classified as “secondary”, developing from a previous systemic disease, or, on the contrary, “primary”, resulting from transcutaneous inoculation of the agent. It can also be classified as “disseminated cutaneous cryptococcosis”, when there is an associated systemic disease, or “localized”, when it is restricted to the skin. This article uses the term “primary cutaneous cryptococcosis” because it is the most widely used and already established in the literature. Historically, the first report of a possible case of primary cutaneous cryptococcosis (PCC) occurred in 1950 by Gancy WM and was published in the Archives of Dermatology and Syphilology. Subsequently, the rare and sporadic reports in the following decades were reviewed and reported in the 1985 publication by Baes & van Cutsem. However, the unequivocal acceptance of the existence of PCC as a distinct disease only occurred in 2003 with the publication by Neville S et al. of the French Cryptococcosis Study Group. The fundamental criterion established to consider it as PCC was the proven absence of systemic disease, whether pulmonary, in the CNS or other location at the time of diagnosis of the cutaneous condition, characterized by a single lesion and, mostly, in an exposed area. These and other clinical criteria, diagnostic confirmation, and therapeutic choice are discussed in detail in the full text.

© 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Cryptococcosis. Etiopathogenesis. Concepts. Classification

Cryptococcosis is a human and animal disease caused by fungi of the genus *Cryptococcus*, an encapsulated yeast with several species, of which the recognized pathogens

[☆] Study conducted at the Department of Infectology, Dermatology, Diagnostic Imaging and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil.

* Corresponding author.

E-mail: silvio.marques@unesp.br (S.A. Marques).

are *Cryptococcus neoformans* and *Cryptococcus gattii*. *C. neoformans* is a cosmopolitan, universal fungus, frequently isolated from pigeon droppings, decaying vegetables and fruits, and causes human disease predominantly in immunocompromised patients.^{1,2} On the other hand, *C. gattii* has a more regionalized distribution, prevailing in tropical and subtropical regions, although it has been isolated in temperate regions. It should be noted that *C. gattii* infects both immunocompromised and immunocompetent patients.^{3,4} *C. gattii* is isolated from soil samples, decaying vegetables, and tree hollows, and has a special ecological association with *Eucalyptus camaldulensis* plantations.^{3,5} In 2015, Hagen F et al.⁶ published an article on sufficient molecular evidence to subdivide *C. neoformans* into two new species and *C. gattii* into four additional new species, namely: *C. neoformans* and *C. deneoformans*; and, the species *C. gattii*, *C. deuterogattii*, *C. bacillosporus*, *C. tetragattii* and *C. decagattii* and also the possibility of hybrid species.⁶ This proposal, although based on multiple molecular data, did not find support among experts, including Kwon-Chung KJ et al.⁷ The latter authors, under various arguments, including the lack of association of specific clinical manifestations with a particular subspecies, propose the use of the name *C. neoformans* complex (*Cryptococcus neoformans* species complex) and *C. gattii* complex (*Cryptococcus gattii* species complex).⁷ This suggestion has been followed by several authors in recent reports.^{8–10}

Cutaneous cryptococcosis can be classified as “secondary” to dissemination from a previous systemic disease or “primary”, by transcutaneous inoculation of the agent. Or, it can be classified as “disseminated cutaneous cryptococcosis”, that is, resulting from systemic disease with a cutaneous lesion originating from hematogenous dissemination of the fungus. Or, on the contrary, it can be classified as “localized”, when restricted to the skin.¹¹ In this article, the term “primary cutaneous cryptococcosis” is used, following the concept of local transcutaneous inoculation, as it is more widely used and already established in the literature.¹²

Classically, in systemic disease, the natural history of cryptococcosis results from inhalation of the fungi and a pulmonary condition that is almost always asymptomatic or oligosymptomatic. In terms of evolution, immediate hematogenous dissemination or the permanence of a quiescent pulmonary focus and subsequent hematogenous dissemination due to an imbalance in the agent-host relationship may occur.¹¹ It is a typical disease of immunocompromised individuals and is considered, in itself, a defining factor for AIDS in HIV-infected individuals, as well as an incidental disease in patients after solid organ transplantation or on prolonged corticosteroid therapy.¹³ Cryptococcosis in immunocompromised patients presents most frequently as involvement of the central nervous system (CNS), with initially indolent manifestations and progressive evolution to severe and potentially fatal meningoencephalitis. An isolated or predominant pulmonary clinical manifestation is not common, but possible. Other organs and systems may be affected, including the skin in up to 15% of AIDS cases; therefore, producing a secondary skin lesion which functions as sentinel of associated systemic involvement.^{11,13} The dermatological clinical presentation of a lesion associated with a systemic focus is distinct from

that resulting from a primary skin lesion and therefore helps in the diagnostic differentiation between “primary” or “secondary” cutaneous cryptococcosis. When the skin lesion is secondary to systemic disease, the most frequent clinical manifestation are multiple lesions, mainly in the cephalic segment, with possible mucosal lesions, albeit uncommon.^{11,14,15} In contrast, the primary cutaneous lesion is a single, polymorphic lesion, most often an infiltrated plaque of varying extent, with a tendency to necrosis and no mucosal involvement.^{11,12}

Primary cutaneous cryptococcosis

History

Sporotrichosis and chromoblastomycosis are mycoses classically accepted as examples of subcutaneous implantation mycoses and primary transcutaneous infection. Other mycoses, which are classically systemic and inhalation-mediated infections, such as coccidioidomycosis, blastomycosis, histoplasmosis, and even paracoccidioidomycosis, may exceptionally be the result of transcutaneous inoculation.^{16,17} However, these events, in these circumstances, constitute rare, exceptional cases and are a clear exception to the rule. The first report of a possible case of primary cutaneous cryptococcosis (PCC) occurred in 1950 by Gancy WM and was published in the Archives of Dermatology and Syphology.¹⁸ This report was followed by rare and sporadic publications in the following decades, with the reported cases associated or not with immunocompromised patients.^{18–21} These publications were reviewed and reported in detail by Baes & van Cutsen in 1985.²² However, the unequivocal acceptance of the existence of PCC as a clinical subtype distinct from classical cryptococcosis and recognized as such occurred in 2003 with the publication of Neville S et al.²³ of the French Cryptococcosis Study Group. In this publication, the authors compared data from 28 patients with a presumptive diagnosis of PCC with those from 80 cases of disseminated classical cryptococcosis with skin lesions and also data from 1866 cases of disseminated cryptococcosis and involvement of organs other than the skin.²³ The basic criterion for considering a presumptive diagnosis of PCC was, evidently, the proven absence of systemic disease, whether pulmonary, in the central nervous system or any other location at the time of diagnosis of the skin condition. Among the various differences observed in the groups studied above, the semiological pattern and location of the lesions were differentiated. The cases of PCC were restricted to single lesions located mainly in exposed areas, sparing the cephalic segment. On the other hand, the cutaneous lesions secondary to systemic disease were almost always multiple, papulonodular, often molluscum contagiosum-like and preferentially located in the cephalic segment. It is worth noting that the same article shows the occurrence of PCC cases in immunocompetent patients, which did not occur in the systemic disease cases studied therein. Therefore, based on this explicit demonstration that these are distinct clinical expressions, the concept of “primary cutaneous cryptococcosis” was consolidated.²³ The criteria that favor suspicion and determine the definitive diagnosis of one or the other form of the disease are



Figure 1 Primary cutaneous cryptococcosis (PCC): Infiltrated, erythematous plaque with raised surface, showing a tumor-like aspect. Rare ulcerated or necrotic spots. Forearm of an immunocompetent 66-year-old male patient, post-trauma.

didactically and clearly demonstrated in tables in this reference article by Neville S et al.²³

Diagnostic criteria. Clinical history and clinical-dermatological examination

The clinical history of the current disease in PCC is variable, ranging from weeks to months. There is not always a history of trauma preceding the lesion, just as there is not always a history of exposure to bird or bat droppings or rural life. The lesions are almost always located in exposed areas subject to trauma, particularly the arm and forearm. The complaint may be of pain and/or local heat. There is no complaint of fever, systemic signs or symptoms. There is often a history of immunosuppressive medication use for different reasons: post-solid organ transplant, corticosteroid therapy for chronic obstructive pulmonary disease, autoimmune diseases, particularly rheumatic joint disease, use of biological immunosuppressants or chemotherapy. When affecting the elderly, even in the absence of medication or an evident cause of immunocompromise, immunosenescence, in itself, may be the contributing factor to be considered.

Clinical suspicion of PCC arises from a single skin lesion located in an exposed area, particularly the upper limbs, with acute or subacute progression, with compatible dermatological clinical characteristics and no signs or symptoms of systemic disease. Semiologically, the lesion is polymorphic, most often infiltrative, tumor-like, ulcerated or not, occasionally leishmaniasis-like, with or without necrotic spots, and rarely cellulitis-like. The lesion diameter is variable and may affect an entire segment of the affected limb, and lesion limits are not always precise. The coloration is erythematous, erythematous-violet, or erythematous-brownish (Figs. 1–5).^{11,12,23–27} On palpation, the consistency may be firm or somewhat soft, gelatinous, due to the large number of fungal elements, their mucoid capsules, and the scarce inflammatory response.¹² Bacterial coinfection and local inflammatory signs are not uncommon. If the diagnosis is delayed, the lesion tends to develop a large diameter, with skin surface necrosis (Figs. 6 and 7). There are multiple differential diagnoses and the use of the PLECT



Figure 2 PCC: Ulceronecrotic lesion with precise limits, absence of inflammatory halo. Forearm of an immunocompetent 58-year-old male patient, post-trauma.



Figure 3 PCC: Ulcerated lesion, clear background, with hemorrhagic spots, islands of intact tissue and infiltrated borders. The photo was taken after debridement. Elbow of a 74-year-old male patient with COPD, on irregular corticosteroid therapy, 10 mg/day. Post-trauma lesion, which occurred during the cleaning of the attic of a Catholic church.

syndromic diagnosis (paracoccidioidomycosis, leishmaniasis, sporotrichosis [*Esporotricose* – portuguese language], chromoblastomycosis and cutaneous tuberculosis) is recommended as an initial guide. The hypotheses of pyoderma gangrenosum, severe bacterial infections, ecthyma gangrenosum including their possible causal agents, and herpes zoster with necrosis should be added to the clinical reasoning in immunocompromised patients. Given the acute or subacute nature of the process, neoplastic diseases are not plausible differential diagnoses.

It is not unusual for the initial suspicion to be of a bacterial or even viral infectious process (herpes zoster) and only after therapeutic failure with the use of antibiotics or antivirals or even worsening while taking them, does the attending physician submit the lesion to histopathological or direct mycological examination. Once the diagnosis of cutaneous cryptococcosis has been established, confirmation of whether it is primarily cutaneous and of the infecting species must follow the academically well-established criteria and steps briefed below.




Figure 4 PCC: (A) Extensive plaque with necrotic, ulcerated spots and pseudovesicles crusts in a 70-year-old male patient, on irregular corticosteroid therapy 5 mg/day, due to arthritis. The patient lived in a rural area. (B) Detail: Presence of a tumor-like lesion with necrotic spots and satellite lesions with pseudovesicles.

Diagnostic confirmation

Diagnostic confirmation is based on the analysis of several criteria:

I - Observation of the agent on direct examination (direct mycological examination). A sample obtained from the lesion by biopsy, curettage, or scraping with a blunt scalpel is gently smeared on a blood count slide, to which drops of Indian ink (or Nanking ink) are added. Or, even in the absence of Indian ink, a smear of a lesion sample treated with drops of saline solution can be used. India ink or saline solution do not penetrate the mucoïd capsule of *Cryptococcus sp.* and, as a result, the capsule stands out, contrasting with the black of the India ink or the pink of the hemorrhagic medium (Fig. 8).²⁸

II - Culture with seeding on Niger seed agar or Sabouraud dextrose agar. Mycosel agar should not be used, as it contains cycloheximide (Actidione®), which inhibits the growth of several species of *Cryptococcus*.^{28,29} The lesion sample for seeding can be obtained by micro biopsy or curettage of the lesion bed. The sample must be collected with maximum antisepsis, avoiding bleeding if possible, and sent to the mycology laboratory as soon as possible in a sterile bottle containing saline solution. The seeded test tube or Petri dish should ideally be kept at 30°-32 °C, but under routine conditions they can be kept at room temperature. The growth of *Cryptococcus spp.* is rapid, already visible macroscopically



Figure 5 PCC: Ulcerated lesion, granular background, with borders framing the lesion in a leishmaniasis-like appearance on the deltoid region of a 31-year-old male patient, a kidney transplant recipient after seven years. The patient was receiving prednisone 5 mg and tacrolimus 0.2 mg/kg/day.




Figure 6 PCC: (A) Infiltrated, extensive lesion, showing nodules, ulcerations, necrotic spots, in the distal region of the arm, forearm and dorsum of the hand of a 77-year-old male patient with COPD, on corticosteroid therapy, 10 mg/day. The patient lived in a rural area. (B) Detail: Nodules, scar retractions, ulceration spots and necrosis.




Figure 7 CCP: (A) Extensive phagedenic and terebrant lesion, with necrotic and ulcerated areas, on the arm, forearm and dorsum of the hand of an 80-year-old male patient on irregular use of corticosteroid therapy 10mg for years, due to arthritis. (B) Erythematous-edematous lesion, with vesicles and bullae, and necrotic area on the dorsum of the hand (Patient from Reference #12).




Figure 8 PCC: Direct mycological examination. (A) Indian ink. (B) Detail: fungal cell with mucoid capsule highlighted by contrast with the black color of Indian ink.

after two to five days, with a yeast-like, creamy or creamy-white color, resembling condensed milk. If seeded on Niger seed medium, it shows a brownish-coffee pigmentation.^{28,29} When seeded in a test tube, immobilized in a vertical position, the culture tends to ‘run’ to the bottom of the tube (Fig. 9A).²⁸

III – Species definition can be obtained from a sample of the original, primary culture, in Niger seed or Sabouraud dextrose medium, and then transplanted onto a medium containing canavanine, glycine, and bromothymol blue (CGB agar). In this method, the original CGB agar has a yellow-green color, but when the transplanted culture is of the *Cryptococcus gattii* complex, the color of the agar changes to cobalt blue in two/three to five days. This color change occurs due to the degradation of creatine into ammonia and a change in the pH of the original CGB agar (pH 5) to an alkaline one (pH 7). Species of the *Cryptococcus neoformans* complex do not produce such changes and the CGB agar remains with its original yellow-green color (Fig. 9B). It is important to know that CGB agar is not indicated for obtaining the primary culture and is only used to differentiate between species.^{30,31} A positive culture is considered the reference evidence for the diagnosis and is essential for academic and research purposes.

IV – Confirmation can be achieved through increasingly popular and widely used technologies such as automated auxanograms, which use samples from the primary culture, and also the use of the proteomic identification technique




Figure 9 PCC: (A) *Cryptococcus* spp. Yeast culture; appearance of condensed milk. (B) *Cryptococcus neoformans* and *C. gattii*. CGB Agar. Yellowish-green tube, original CGB agar – *C. neoformans*. Cobalt blue tube, modified CGB agar – *C. gattii*.

(MALDI ToF MS). These methods are available in commercial reference laboratories and better-equipped university hospitals. These are methods that provide fast, reliable results and identify species belonging to the *C. neoformans* or *C. gattii* complexes.

V – Molecular method: Through extraction and amplification of fungal DNA by polymerase chain reaction (PCR) and sequencing of the Internal Transcribed Spacer (ITS) of ribosomal DNA. Species identification, whether *Cryptococcus neoformans* complex or *Cryptococcus gattii* complex, results from the use of specific primers in the amplification and identification of serotypes. The molecular method, although very important from an academic point of view, is restricted to research and available in a few reference laboratories.³²

VI – Histopathological examination of a 5-punch or spindle-shaped biopsy with a scalpel is indicated, avoiding necrotic areas. The sample should be sent to the pathology laboratory immersed in 10% buffered formalin. Histopathological findings are characterized by moderate epidermal hyperplasia, with possible ulceration or necrosis foci, and scarce chronic inflammatory infiltrate in the dermis. Histiocytes and rare or few giant cells are observed. The infiltrate contains a variable number of lymphocytes, eosinophils, and neutrophils. The hematoxylin and eosin staining shows clear spaces in the dermis that correspond to areas occupied by numerous fungal elements producing “mucoïd masses” irregularly permeated by the inflammatory infiltrate. The fungi are visible with the hematoxylin and eosin staining and are highlighted and more characteristically recognized with the mucicarmine and alcian-blue stainings, as these are capable of staining the mucoïd capsule of the fungus. *Cryptococcus* species are also stained with periodic acid-Schiff (PAS) and silver-methenamine (Grocott-Gomori method). The Grocott-Gomori staining, in particular, allows the observation and quantification of the large number of fungal elements, characterized by single cells, stained in black, measuring 5 to 15 μm in diameter, contrasting with the greenish or yellowish background. Fungal cells usually present no buds or only one, but two buds are possible and, rarely, the presence of hyphae.³³ PAS and Grocott-Gomori stains reveal the presence of fungal elements but do not allow absolute histological certainty in the diagnosis of cryptococcosis (Figs. 10–12).^{34,35} Non-encapsulated variants or those with small capsules, which are more difficult to recognize, should be considered, and it is suggested that they are associated with greater pathogenicity and greater inflammatory response.^{36,37}

VII – The serological method: by latex agglutination to detect the polysaccharide capsular antigen of *Cryptococcus sp.* It is performed in blood, cerebrospinal fluid, bronchoalveolar lavage, or urine samples. This method, in such samples, has a sensitivity of 95% and a specificity of 98%, in which titers $>1/4$ suggest infection and $>1/8$ suggest active disease. When PCC is suspected, the objective is to determine that, at least in serum and cerebrospinal fluid samples, the latex agglutination test is negative, which would indicate the absence of systemic involvement with 98% certainty.³⁸ Also, the cryptococcal antigen-lateral flow immunochromatographic assay (CrAg-LFA), has been used for detection of the capsular antigen.³⁹




Figure 10 PCC: (A) Histopathology. Slightly acanthotic epidermis and dermal inflammatory infiltrate, surrounding a large clear area. (Hematoxylin & eosin $\times 40$). (B) Detail showing histiocytic and lymphocytic infiltrate, basophilic degeneration of collagen and fungal cells with basophilic central nucleus and mucoïd capsule (Hematoxylin & eosin $\times 200$).

VIII – Complementary tests: investigation of systemic involvement is mandatory, even in the absence of signs, systemic symptoms or the presence of negative serology. Ideally, the complementary investigation involves a specialized clinical neurological and cerebrospinal fluid evaluation, if indicated. Complementary tests, such as computed tomography of the skull, chest, and abdomen can be used. The complementary laboratory investigation aims to exclude HIV and HTLV-1 infections and to perform other hematological and biochemical tests, including those for therapeutic monitoring purposes.

Treatment

Since PCC is an uncommon condition, there are no therapeutic trials gathering evidence to consolidate first- or second-line indications. It is necessary to identify possible aggravating factors in the clinical case being monitored to guide the choice of drug and route of administration, using the following parameters:

I – Those related to the patient in a holistic manner: age, profession, socioeconomic status, nutritional status, and access to medications. Inquire about the presence




Figure 11 PCC – (A) Alcian blue staining showing *Cryptococcus* stained in blue, including the mucoid capsule. (B) High magnification detail.




Figure 12 PCC: Mucicarmin staining showing *Cryptococcus* stained in dark red color including part of the mucoid capsule.

of comorbidities, current immunosuppressive therapy, and daily medication, and also about the abusive consumption of alcohol or tobacco.

II - Those related to the lesion itself: time of disease, extent of the lesion, presence or absence of necrosis, previous treatments, need or absence for debridement or drainage.

III - Information obtained through imaging tests and by serological, hematological and biochemical laboratory investigations. Based on the above set of data, the definition of mild/moderate or severe condition, according to the perception of the attending physician, will guide the choice of therapy and the need or absence for procedures or even hospitalization. Mild and moderate cases respond

satisfactorily to the use of azole derivatives, with fluconazole at a dose of 300 to 400 mg/day for three to six months being effective, as well as itraconazole at a dose of 200 to 400 mg/day, also for three to six months.⁴⁰ Azole derivatives act by inhibiting the CYP-450-dependent enzyme 14- α demethylase and, consequently, by inhibiting the conversion of lanosterol into ergosterol, reducing the formation of the fungus outer cell membrane and its replication.⁴¹ The clinical response is usually evident at the end of 30 days of treatment and complete healing should occur within six months.^{11,12,40} If the response is slow, it is necessary to check the plasma levels of the azole derivatives in use and verify a possible interference with absorption. It is necessary to bear in mind that azole derivatives are fungistatic drugs and that fungal growth inhibition values obtained in *in vitro* experiments are not necessarily transferable to human patients. Similarly, attention is due to possible drug interactions, since the list of drugs that interact with azole derivatives is not small.⁴¹ Itraconazole is a potent inhibitor of the CYP3A4 hepatic metabolic pathway, and fluconazole is a potent inhibitor of the CYP2C9 pathway and a moderate inhibitor of the CYP3A4 pathway.^{41,42} Therefore, the predictable drug interaction in solid organ transplant recipients using tacrolimus, sirolimus, or cyclosporine should be considered, as well as patients using warfarin and also taking into account the polypharmacy that elderly patients often use.⁴¹⁻⁴⁵ Itraconazole, in particular, has reduced plasma levels when associated with rifampicin and such interaction can be a cause of therapeutic failure.^{40,41} Itraconazole in particular has increased absorption under acidic pH; therefore, it is best prescribed after large meals accompanied by ingestion of citrus fruits juice.⁴³

Severe cases and, exceptionally, moderate cases, require intravenous treatment with fluconazole or amphotericin B deoxycholate or amphotericin B lipid formulation. Amphotericin B is an antibiotic with antifungal properties, derived from *Streptomyces nodosus*, which acts on the ergosterol of the cytoplasmic membrane of the fungal cell with dose-dependent fungistatic or fungicidal properties.^{41,46} It does not promote inhibition of cytochrome P-450; therefore, pharmacological interaction is uncommon. The renal excretion of amphotericin B as an active drug is between 2% and 5% and it is a dialyzable drug, although there is controversy.^{46,47} If using amphotericin B deoxycholate (classical Amph. B), the daily dose used is 0.5 to 1.0 mg/kg/day or on alternate days, restricting the daily dose to a maximum of 50 mg/infusion, regardless of the patients weight. To minimize the pyrogenic effect associated with the release of pro-inflammatory cytokines by classical Amph. B, the initial doses should be lower, for example: 20 mg/day for two days, followed by 30 mg/day for two days and 40 mg/day for two days until stabilizing at the expected daily dose per kilogram of weight.⁴⁸ Classical Amph. B has significant adverse effects, especially renal, resulting in vasoconstriction of afferent arterioles and renal ischemia, inducing renal acidosis, hypokalemia, and hypomagnesemia.^{49,50} Nephrotoxicity is aggravated by the concomitant use of drugs with nephrotoxic potential, particularly the use of non-steroidal anti-inflammatory drugs.^{49,50} Therefore, renal function and electrolytes must be periodically monitored, at the frequency determined by laboratory results. It is mandatory that, before starting treatment with classical Amph. B,

the following parameters be predefined: blood count, renal function, electrolytes, liver enzymes, lipase, amylase, and ECG, in addition to other laboratory parameters of interest. Patients with cardiac conduction alterations are at risk and require follow-up with cardiological and electrolyte monitoring on an almost daily basis. To reduce predictable adverse effects, the suggested prescription is: a daily dose of classic Amph. B, with peripheral venous access, diluted in 500 mL of glucose solution (in 5% dextrose, since saline solution precipitates the amphotericin salt).⁴⁸ The following should be added, diluted in each infusion: 50 mg of hydrocortisone, used to eliminate or reduce the pyrogenic effects, and 1000 units of heparin, with the purpose of eliminating or reducing the risks of thrombophlebitis induced by classic Amph. B.^{48,51} After running this combined infusion for six hours, a rapid phase of 250–500 mL of saline solution is prescribed to partially reduce the effects of renal aggression.^{48,49} Potassium and magnesium (K+ and Mg+) replacement should be performed daily, orally or intravenously, as needed. As a therapeutic alternative, despite its high cost, amphotericin B lipid complex (ABLC) is recommended, which is characterized by good tissue distribution, or liposomal amphotericin B (L-AmB), which is better diffused in the CNS.⁵² These are effective formulations and are indicated for reducing adverse effects, particularly lower nephrotoxicity. Lipid formulations are used via intravenous infusion, previously reconstituted in sterile distilled water and subsequently diluted in 5% dextrose solution, daily and in doses of 3 to 5 mg/kg/day.^{49,50,52–54} A promising strategy for the different types of amphotericin B is to reduce the time of therapeutic use of amphotericin to 15 days (as if it were a loading dose) and then transition to an azole derivative, daily and at high doses.^{52,55} This strategy allows the use of higher doses of amphotericin B (classic or lipid complex), for a shorter period of time, with lesser adverse effects and reduces the length of hospital stay. This therapeutic suggestion has already been used in the treatment of paracoccidioidomycosis and histoplasmosis.^{52,55} The combination of amphotericin B deoxycholate and fluconazole to maximize treatment is possible and supported by the literature.⁵⁶ Associated adjuvant interventions, such as debridement of the lesion with removal of necrotic tissue through curettage of the lesion bed, or draining of possible purulent content, have been suggested, but at first, this is an exceptional and restricted conduct.⁵⁷ Similarly, the association of antibiotic coverage is done on a case-by-case basis. If the patient has HIV infection and/or AIDS, it is necessary to consider whether or not to continue with azole derivatives after healing and apparent cure. Regarding histoplasmosis, in patients with AIDS, maintenance with azoles, after apparent cure, can be discontinued if the patient has a CD4 count ≥ 200 cells/mm³.⁵⁸ However, in relation to primary cutaneous cryptococcosis, there is no evidence in this regard in the literature.

Prognosis

At first, usually evolution under correct treatment is satisfactory and shows resolution, albeit slow in some cases. Response time to treatment will be individual and according to the severity parameters of the case as a whole

and the medication used. Cases treated with amphotericin B deoxycholate or lipid formulation should show faster improvement. The same is true with the use of high-dose azole derivatives. It should be considered that depending on the drug and the doses used, adverse effects and/or drug interactions may manifest earlier or later.

In the literature, there are questions about the possible risk of hematogenous dissemination of *Cryptococcus spp.* from the cutaneous PCC lesion or after treatment.⁵⁹ This is a valid question, since it is necessary to take into account the risks associated with systemic corticosteroid therapy, if employed, which is certainly the pharmacological iatrogenesis with the greatest risk for opportunistic infections and to which special attention must be paid.⁶⁰ There are numerous reports that provide reassurance regarding the absence of risks of dissemination of the cutaneous disease, even in immunocompromised patients, as long as they are adequately treated.^{11,12,23,24,27,61–63}

However, there is a recent publication in the literature describing the case of a 64-year-old patient who had disseminated and fatal cryptococcosis two years after treatment for PCC diagnosed as a single lesion after trauma in the parietal region. At the time of the cutaneous lesion, no other comorbidities were identified and the patient was considered presumably immunocompetent. And, in the discussion of the case, the authors reported textually: "This is the first case reported of a fatal cryptococcal meningoencephalitis case developing two years after a cured primary cutaneous cryptococcal infection".⁶⁴ However, in this case report two pieces of information differ from what is expected in cases of PCC: first, the skin lesion was resistant to treatment with up to 600 mg/day of fluconazole, with a MIC of 32 $\mu\text{m}/\text{mL}$, which is unusual in the authors practice and in the literature reports. The patient only responded to liposomal amphotericin B 3 mg/kg/day for one month. Second, the investigation of systemic disease, at the time of the cutaneous event, was limited to chest and abdominal CT, with no mention of neurological, tomographic, cerebrospinal fluid, or serological investigation. These data call into question the mention that there was no systemic disease, which had not yet been identified at the time of the initial cutaneous event. Therefore, the authors claim that the case represented systemic disease due to the reactivation of a latent primary cutaneous focus is not entirely unequivocal. An even more challenging case is the report by Amaral et al.⁶⁵ of a 68-year-old patient, a former alcoholic with a smoking history of 100 packs/year, who complained of headache for three days. The patient also had had a lesion on the forearm for a month, which was completely superimposable on semiology to the lesions observed in PCC. During clinical investigation, the cerebrospinal fluid (CSF) showed evidence of lymphocytic meningitis attributed to cryptococcosis and specific serology, by latex agglutination, in the same CSF sample with a titer of 1/1024, findings fully compatible with the diagnosis of meningoencephalitis due to *Cryptococcus spp.* Therefore, depicting a PCC-like cutaneous picture, confirmed by histopathology and culture (*Cryptococcus neoformans*) and with concomitant specific neurological disease.⁶⁵ The only disagreement regarding the interpretation of the case was mentioning that the patient was immunocompetent, when he had been using inhaled corticosteroids for ten years due to chronic obstructive pulmonary disease resulting from

smoking. These case reports certainly require paying close attention to details, formulating prognosis on a case-by-case basis, and evaluating the several variables indicated above. In any case, these reports must be mentioned and can be used as a warning regarding prognosis and constitute a significant contribution to the fundamental issue, which is adequate systemic investigation when there is a presumptive diagnosis of primary cutaneous cryptococcosis.

Conclusion

Primary cutaneous cryptococcosis is an uncommon emerging clinical form, with reports in numerous tropical, subtropical and temperate countries, presented at scientific meetings and dermatology congresses and published in different journals. Clinical suspicion is based on the knowledge that it occurs particularly in immunocompromised individuals but is not exclusive to them. Semiologically, it is polymorphic, with a gelatinous consistency upon palpation, and located in a single exposed area of the body. There are well-established classification and diagnostic criteria, among which culture is the reference method. These criteria must be accurately observed and have to be demonstrated when reporting cases. Treatment is successful with the use of azole derivatives or amphotericin B deoxycholate or amphotericin B lipid formulation. Long-term follow-up is beneficial and recommended.

Financial support

None declared.

Authors' contributions

Silvio Alencar Marques: Drafting and editing of the manuscript; approval of the final version of the manuscript.

Rosângela Maria Pires de Camargo: Approval of the final version of the manuscript.

Conflicts of interest

None declared.

Acknowledgements

To Anna Carolina Miola and Marina Dias for the diagnosis and care of the patient shown in Fig 5. To Eliete Correa Soares for the photographic documentation of the cases. To Mariangela E A Marques for the histopathological documentation and histopathological diagnostic support for the cases shown here. To the Head and Resident Physicians of Dermatology for the care of some of the cases presented.

References

- Li SS, Mody CH. Cryptococcus. *Proc Am Thorac Soc*. 2010;7:186–96.
- Maziarsz EK, Perfect JR. Cryptococcosis. *Infect Dis Clin North Am*. 2016;30:179–206.
- MacDougall L, Fyfe M, Romney M. Risk factor for *Cryptococcus gattii* infection, British Columbia, Canada. *Emerg Infect Dis*. 2011;17:193–9.
- Saidykhan L, Onyishi CU, May RC. The *Cryptococcus gattii* species complex: unique pathogenic yeasts with understudied virulence mechanisms. *PLoS Negl Trop Dis*. 2022;16:e0010916.
- Lazera MS, Cavalcanti MA, Trilles L, Nishikawa MM, Wanke B. *Cryptococcus neoformans* var. *gattii* - evidence for a natural habitat related to decaying wood in a pottery tree hollow. *Med Mycol*. 1998;36:119–22.
- Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, et al. Recognition of seven species in the *Cryptococcus gattii*/*Cryptococcus neoformans* species complex. *Fungal Genet Biol*. 2015;78:16–48.
- Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, et al. The case of adopting the "species complex" nomenclature for the etiologic agent of cryptococcosis. *mSphere*. 2017;2:e00357-16.
- Bahn YS, Sun S, Heitman J, Lin X. *Cryptococcus neoformans* species complex. *Microbiology (Reading)*. 2020;166:797–9.
- Wang YH, Lan J, Lin SH. Primary cutaneous cryptococcosis. *JAMA Dermatol*. 2024;60:995–6.
- Taverna CG, Arias BA, Firacative C, Vivot ME, Szusz W, Vivot W, et al. Genotypic diversity and antifungal susceptibility of clinical isolates of *Cryptococcus gattii* species complex from Argentina. *Mycopathologia*. 2023;188:51–61.
- Noguchi H, Matsumoto T, Kimura U, Hiruma M, Kusuhara M, Ihn H. Cutaneous Cryptococcosis. *Med Mycol J*. 2019;60:101–7.
- Marques SA, Bastazini I Jr, Martins ALGP, Barreto JA, D'Elia MPB, Lastória JC, et al. Primary cutaneous cryptococcosis in Brazil: report of 11 cases in immunocompetent and immunosuppressed patients. *Int J Dermatol*. 2012;51:780–4.
- Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. *Cryptococcal Active Surveillance Group*. *J Infect Dis*. 1999;179:449–54.
- Santiso GM, Messina F, Gallo A, Marín E, Depardo R, Arechavala A, et al. Tongue lesion due to *Cryptococcus neoformans* as the first finding in an HIV-positive patient. *Rev Iberoam Micol*. 2021;38:19–22.
- Wong DJY, Stanley P, Paddle P. Laryngeal cryptococcosis associated with inhaled corticosteroid use: case report and literature review. *Front Surg*. 2017;4:63.
- Wilson JW. Cutaneous (chancriform) syndrome in deep mycosis. *Arch Dermatol*. 1963;87:81–5.
- Castro RM, Cucé LC, Fava Neto C. Paracoccidioidomycosis. Accidental inoculation "in anima nobile". Report of a case. *Med Cutan Ibero Lat Am*. 1975;3:189–92.
- Gandy WM. Primary cutaneous cryptococcosis. *Arch Derm Syphilol*. 1950;62:97–104.
- Hurwich BJ, Domonkos AN. Primary cutaneous cryptococcosis. Seroinmunologic and fluorescent antibody studies. *N Y State J Med*. 1970;70:1075–9.
- Miura T, Akiba H, Saito N, Seiji M. Primary cutaneous cryptococcosis. *Dermatologica*. 1971;142:374–9.
- Lacobellis FW, Jacobs MI, Cohen RP. Primary cutaneous Cryptococcosis. *Arch Dermatol*. 1979;115:984–5.
- Baes H, van Cutsem J. Primary cutaneous cryptococcosis. *Dermatologica*. 1985;171:357–61.
- Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. *Clin Infect Dis*. 2003;36:337–47.
- Christianson JC, Engber W, Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. *Med Mycol*. 2003;41:177–88.

25. Romiti R, Hirayama ALS, Porro AM, Gonçalves HS, Miot LDB, Durães SMB, et al. Infections in the era of immunobiologicals. *An Bras Dermatol.* 2024;99:167–80.
26. Shalon G, Horev A. Primary cutaneous cryptococcosis: an unusual injection site infection. *Case Rep Dermatol.* 2020;12:138–43.
27. Belda Jr W, Casolato ATS, Luppi JB, Passero LFD, Criado PR. Primary cutaneous cryptococcosis caused by *Cryptococcus gattii* in an elderly patient. *Trop Med Infect Dis.* 2022; 7:206.
28. Kwon-Chung KJ, Bennett JE. Cryptococcosis. In: Kwon-Chung KJ, Bennett JE, editors. *Medical Mycology*. Philadelphia: Lea & Febiger; 1992. p. 397–446.
29. Bonifaz A. Criptococcosis. In: Bonifaz A, editor. *Micologia Médica Básica*. México DC: McGraw-Hill; 2010. p. 303–16.
30. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of *Cryptococcus neoformans* var. *neoformans* (serotypes A and D) and *Cryptococcus neoformans* var. *gattii* (serotypes B and C). *J Clin Microbiol.* 1982;15:525–37.
31. Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfel SL, Wengenack NL. Identification of *Cryptococcus gattii* by use of L-canavanine, glycine, bromothymol blue medium and DNA sequencing. *J Clin Microbiol.* 2009;47:3669–72.
32. Nascimento E, Silva MENB, Martinez R, Kress MRZ. Primary cutaneous cryptococcosis in an immunocompetent patient due to *Cryptococcus gattii* molecular type VGI in Brazil: a case report and review of literature. *Mycosis.* 2014;57:442–7.
33. Weedon D, Strutton G. Mycosis and algal infections. In: Weedon D, Strutton G, editors. *Skin pathology*. 2nd Edition Edinburgh Churchill & Livingstone; 2002. p. 659–90.
34. Noble RC, Fajardo LF. Primary cutaneous cryptococcosis: review and morphologic study. *Am J Clin Pathol.* 1972;57:13–22.
35. Chu AC, Hay RJ, MacDonald DM. Cutaneous cryptococcosis. *Br J Dermatol.* 1980;103:95–100.
36. Severo LC, Londero AT, Martins SC, Reolon M, Geyer RG. Probable pulmonary cryptococcosis caused by a non-capsulated *Cryptococcus neoformans*. *Rev Inst Med Trop São Paulo.* 1981;23:283–6.
37. Morales-Lópes SE, Garcia-Effron G. Infections due to rare *Cryptococcus* species. A literature review. *J Fungi (Basel).* 2021;7:279.
38. Moretti ML, Resende MR, Lazera MS, Colombo AL, Shikanai-Yasuda MA. Guidelines in cryptococcosis-2008. *Rev Soc Bras Med Trop.* 2008;41:524–44.
39. Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. *Clin Infect Dis.* 2014;58:113–6.
40. Morales EG, Guidi M, Peterka T, Rabuffetti A, Blum R, Mainetti C. Primary cutaneous cryptococcosis due to *Cryptococcus neoformans* in an immunocompetent host treated with itraconazole and drainage: case report and review of the literature. *Case Rep Dermatol.* 2021;13:89–97.
41. Gupta AK. Systemic antifungal agents. In: Wolverson SE, editor. *Comprehensive dermatologic drug therapy*. 3rd ed. Edinburg: Elsevier – Saunders; 2013. p. 98–120.
42. Niwa T, Imagawa I, Yamazaki H. Drug interactions between nine antifungals agents and drugs metabolized by cytochromes P540. *Curr Drug Metab.* 2014;15:561–79.
43. Dodds-Ashley E. Management of drug and food interactions with azole antifungals agents in transplant recipients. *Pharmacotherapy.* 2010;30:842–54.
44. Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Cutaneous cryptococcosis in solid organs transplant recipients. *Med Mycol.* 2010;48:785–91.
45. Ferry T, Moos D, Radenne S, Bienvenu AL, Kanitakis J. Primary cutaneous cryptococcosis in a liver transplant recipient. *BMJ Case Rep.* 2011;2011:bcr0220113814.
46. Kwon-Chung KJ, Bennett JE. Principles of Antifungal Therapy. In: Kwon-Chung KJ, Bennett JE, editors. *Medical mycology*. Philadelphia: Lea & Febiger; 1992. p. 81–102.
47. Marques SA, Merlotto MR, Müller-Ramos P, Marques MEA. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure. *An Bras Dermatol.* 2019;94:355–7.
48. Dillon NL, Marques SA. Vantagens e desvantagens da anfotericina B no tratamento da paracoccidiodomicose. *An Bras Dermatol.* 1990;65:226–7.
49. Falci DR, da Rosa FB, Pasqualoto AC. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life analysis. *Mycoses.* 2015;58:104–12.
50. Cavassin FB, Queiroz Filho F, Colombo AL. Terapia antifúngica. In: Salomão E, editor. *Salomão R: Infectologia. Bases clínicas e tratamento*. 2nd Edição Guanabara Koogan; 2023. p. 675–84.
51. Lastória JC, Marques SA, Dillon NL, Lastória S. Prevenção da tromboflebite em pacientes tratados com anfotericina B. *Med Cut ILA.* 1995;22:377–82.
52. Peçanha PM, Souza S, Falqueto A, Grão-Veloso TR, Lírio LV, Ferreira Jr CUG, et al. Amphotericin B lipid complex in the treatment of severe paracoccidiodomycosis: a case series. *Int J Antimicrob Agents.* 2016;48:428–30.
53. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. *Drugs.* 2013;73:919–34.
54. Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. *Clin Infect Dis.* 2019;68:S260–74.
55. Araúz AB, Papineni P. Histoplasmosis. *Infect Dis Clin North Am.* 2021;35:471–91.
56. Markman DL, Oliveira PPB, Takano DM, Cambuim IIFN. Cutaneous and pulmonar cryptococcosis. *An Bras Dermatol.* 2020;95:395–7.
57. Wang J, Bartelt L, Yu D, Joshi A, Weinbaum B, Pierson T, et al. Primary cutaneous cryptococcosis treated with debridement and fluconazole monotherapy in an immunosuppressed patient: a case report and review of the literature. *Case Rep Infect Dis.* 2015;2015:131356.
58. Negroni R, Helou SH, López-Daneri G, Robles AM, Arechavala AI, Bianchi MH. Interruption of antifungal secondary prophylaxis in AIDS-related histoplasmosis. *Rev Iberoam Micol.* 2004;21:75–8.
59. Souza CS, Takada MH, Ambiel MV, Nakai VT. Primary cutaneous cryptococcosis: the importance of the early diagnosis. *An Bras Dermatol.* 2021;96:482–4.
60. Tavares LCP, Caetano LVN, Ianhez M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. *An Bras Dermatol.* 2024;99:259–68.
61. Lopez MF, Francisco R, Pérez-Martínez I, García BG, Allende BV, Asensi V, et al. Pyoderma gangrenosum and primary cutaneous cryptococcosis in an ulcerative colitis patient. *Gastroenterol Hepatol.* 2019;42:107–8.
62. Nishiyama-Fujita Y, Kondapi DS, Parkerson GR 3rd, Xu Y. Primary cutaneous cryptococcosis of nose with extensive tissue destruction: a rare case report. *Ear Nose Throat J.* 2022;1455613221126324.
63. Panza F, Montagmani F, Baldino G, Custozza C, Turambello M, Fabbiani M. Primary cutaneous cryptococcosis in an immunocompetent patient: diagnostic workflow and choice of treatment. *Diagnostics (Basel).* 2023;13:3149.
64. Romiopoulou I, Pana ZD, Pырpasopoulou A, Linardou I, Avidelidi E, Sidiropoulou S, et al. Fulminant cryptococcal meningoencephalitis after successful treatment of primary cutaneous cryptococcosis. *Germes.* 2020;10:388–91.
65. Amaral DM, Rocha RCC, Carneiro LEP, Vasconcelos DM, Abreu MAMM. Disseminated cryptococcosis manifested as a single tumor in an immunocompetent patient, similar to the cutaneous primary forms. *An Bras Dermatol.* 2016;91:29–31.